[go: up one dir, main page]

WO2023047376A3 - Peptide constructs for targeted protein degradation - Google Patents

Peptide constructs for targeted protein degradation Download PDF

Info

Publication number
WO2023047376A3
WO2023047376A3 PCT/IB2022/059128 IB2022059128W WO2023047376A3 WO 2023047376 A3 WO2023047376 A3 WO 2023047376A3 IB 2022059128 W IB2022059128 W IB 2022059128W WO 2023047376 A3 WO2023047376 A3 WO 2023047376A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
seq
targeted protein
protein degradation
degradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2022/059128
Other languages
French (fr)
Other versions
WO2023047376A2 (en
Inventor
Maria GORNA
Matylda IZERT
Maria KLIMECKA
Patrycja SZYBOWSKA
Anna ANTOSIEWICZ
Piotr TWARDOWSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Uniwersytet Warszawski
Original Assignee
Uniwersytet Warszawski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski filed Critical Uniwersytet Warszawski
Publication of WO2023047376A2 publication Critical patent/WO2023047376A2/en
Publication of WO2023047376A3 publication Critical patent/WO2023047376A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/04—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The subject of the invention is a peptide construct comprising a first peptide linked to a second peptide, wherein the first peptide binds a first protein which is degradation target, and the second peptide binds a second protein that is able to initiate degradation of the first protein, wherein the first peptide has a sequence selected from SEQ ID NO. 1-7, and the second peptide has a sequence selected from SEQ ID NO. 8-12 and SEQ ID NO. 28-29. The invention relates also to the use of a peptide having a sequence selected from SEQ ID NO. 1-7 as an anchor in a degrader for targeted protein degradation and the use of a peptide having a sequence selected from SEQ ID NO. 8-12 or SEQ ID NO. 28-29 as a warhead in a degrader for targeted protein degradation.
PCT/IB2022/059128 2021-09-24 2022-09-26 Peptide constructs for targeted protein degradation Ceased WO2023047376A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL439032A PL439032A1 (en) 2021-09-24 2021-09-24 Peptide constructs for targeted protein degradation
PLPL439032 2021-09-24

Publications (2)

Publication Number Publication Date
WO2023047376A2 WO2023047376A2 (en) 2023-03-30
WO2023047376A3 true WO2023047376A3 (en) 2023-06-01

Family

ID=84367080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/059128 Ceased WO2023047376A2 (en) 2021-09-24 2022-09-26 Peptide constructs for targeted protein degradation

Country Status (2)

Country Link
PL (1) PL439032A1 (en)
WO (1) WO2023047376A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010419A2 (en) * 2000-07-31 2002-02-07 Wyeth CHARACTERIZATION OF A FtsZ BINDING SITE AND USES THEREOF
WO2008054881A2 (en) * 2006-06-07 2008-05-08 The Penn State Research Foundation Antibacterial and plasmid elimination agents
WO2010141468A1 (en) * 2009-06-01 2010-12-09 Way Jeffrey C Methods and molecules for yield improvement involving metabolic engineering
WO2020187711A1 (en) * 2019-03-19 2020-09-24 Quadrucept Bio Limited Multimers
WO2020237066A2 (en) * 2019-05-23 2020-11-26 President And Fellows Of Harvard College Gene editing in diverse bacteria

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002010419A2 (en) * 2000-07-31 2002-02-07 Wyeth CHARACTERIZATION OF A FtsZ BINDING SITE AND USES THEREOF
WO2008054881A2 (en) * 2006-06-07 2008-05-08 The Penn State Research Foundation Antibacterial and plasmid elimination agents
WO2010141468A1 (en) * 2009-06-01 2010-12-09 Way Jeffrey C Methods and molecules for yield improvement involving metabolic engineering
WO2020187711A1 (en) * 2019-03-19 2020-09-24 Quadrucept Bio Limited Multimers
WO2020237066A2 (en) * 2019-05-23 2020-11-26 President And Fellows Of Harvard College Gene editing in diverse bacteria

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE Geneseq [online] 21 January 2021 (2021-01-21), "Escherichia coli SSB protein fragment (C9), SEQ ID 517.", XP002808672, retrieved from EBI accession no. GSP:BIQ83778 Database accession no. BIQ83778 *
IZERT MATYLDA ANNA ET AL: "Applications of Bacterial Degrons and Degraders ? Toward Targeted Protein Degradation in Bacteria", FRONTIERS IN MOLECULAR BIOSCIENCES, vol. 8, 7 May 2021 (2021-05-07), XP055849863, DOI: 10.3389/fmolb.2021.669762 *
KATHLEEN E. MCGINNESS ET AL: "Engineering Controllable Protein Degradation", MOLECULAR CELL, vol. 22, no. 5, 8 June 2006 (2006-06-08), AMSTERDAM, NL, pages 701 - 707, XP055434804, ISSN: 1097-2765, DOI: 10.1016/j.molcel.2006.04.027 *
LI YALI ET AL: "Analysis of peptides and proteins in their binding to GroEL", JOURNAL OF PEPTIDE SIENCE, vol. 16, no. 12, 2 September 2010 (2010-09-02), Hoboken, USA, pages 693 - 700, XP093025351, ISSN: 1075-2617, DOI: 10.1002/psc.1288 *
LIEBSCHER MARKUS ET AL: "Rational Design of Novel Peptidic DnaK Ligands", CHEMBIOCHEM, vol. 11, no. 12, 5 August 2010 (2010-08-05), pages 1727 - 1737, XP093025360, ISSN: 1439-4227, DOI: 10.1002/cbic.201000166 *
MORREALE FRANCESCA ESTER ET AL: "BacPROTACs mediate targeted protein degradation in bacteria", BIORXIV, 10 June 2021 (2021-06-10), XP055849853, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2021.06.09.447781v1.full.pdf> [retrieved on 20211011], DOI: 10.1101/2021.06.09.447781 *
PARK ET AL: "Structural Basis of SspB-tail Recognition by the Zinc Binding Domain of ClpX", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 367, no. 2, 27 February 2007 (2007-02-27), pages 514 - 526, XP005907118, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2007.01.003 *
TROUP ROBERT I. ET AL: "Current strategies for the design of PROTAC linkers: a critical review", EXPLORATION OF TARGETED ANTI-TUMOR THERAPY, vol. 1, no. 5, 30 October 2020 (2020-10-30), XP055828975, Retrieved from the Internet <URL:https://www.explorationpub.com/uploads/Article/A100218/100218.pdf> DOI: 10.37349/etat.2020.00018 *
ZAHN MICHAEL ET AL: "Structural Studies on the Forward and Reverse Binding Modes of Peptides to the Chaperone DnaK", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 425, no. 14, 2 April 2013 (2013-04-02), pages 2463 - 2479, XP028574754, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2013.03.041 *

Also Published As

Publication number Publication date
PL439032A1 (en) 2023-03-27
WO2023047376A2 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
EP4389898A3 (en) T cell receptors
EP4524236A3 (en) Anti-vegf protein compositions and methods for producing the same
IN2014CN02050A (en)
AR076508A1 (en) IMMUNOGLOBULIN WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
PE20131413A1 (en) IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
WO2011156380A3 (en) Protein-containing adhesives, and manufacture and use thereof
WO2020146902A3 (en) Anti-variable muc1* antibodies and uses thereof
EP2508601A3 (en) Tem8 peptides and vaccines comprising the same
EP4374913A3 (en) Novel human serum albumin mutant
WO2016130628A8 (en) Griffithsin mutants
WO2020044296A3 (en) Recombinant lectin variants
RU2022100555A (en) NEW PEPTIDE
HK1215441A1 (en) Human serum albumin binding compounds and fusion proteins thereof
WO2019094938A3 (en) Methods and compositions for the treatment of wounds
WO2008113536A8 (en) Neurotrophic peptides
WO2023250384A3 (en) Crispr-cas effector polypeptides and methods of use thereof
EA202190531A1 (en) COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS AND METHODS OF THEIR APPLICATION
WO2023047376A3 (en) Peptide constructs for targeted protein degradation
KR20180084352A (en) Novel piscidin peptide from Rock bream and uses thereof
WO2010057242A3 (en) Vaccine
EP3916005A3 (en) Immunogenic composition
EP4282960A3 (en) Modified lipase and use thereof
WO2018232062A8 (en) Macrocyclic polypeptides
MX380750B (en) Pharmaceutical composition for treating and/or preventing cancer
EA201290384A1 (en) VIRAL CITRULINED PEPTIDES AND THEIR APPLICATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22814502

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22814502

Country of ref document: EP

Kind code of ref document: A2